Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorRoutila, Johannes
dc.contributor.authorBilgen, Türker
dc.contributor.authorSaramaki, Outi
dc.contributor.authorGrenman, Reidar
dc.contributor.authorVisakorpi, Tapio
dc.contributor.authorWestermarck, Jukka
dc.contributor.authorVentela, Sami
dc.date.accessioned2022-05-11T14:48:07Z
dc.date.available2022-05-11T14:48:07Z
dc.date.issued2016
dc.identifier.issn0904-2512
dc.identifier.issn1600-0714
dc.identifier.urihttps://doi.org/10.1111/jop.12372
dc.identifier.urihttps://hdl.handle.net/20.500.11776/10603
dc.description.abstractBackgroundCIP2A, an inhibitor of PP2A tumour suppressor function, is a widely overexpressed biomarker of aggressive disease and poor therapy response in multiple human cancer types. MethodsCIP2A and DPPA4 copy number alterations and expression were analysed by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in different cell lines and a tissue microarray of 52 HNSCC patients. Results were correlated with patient survival and other clinicopathological data. ResultsCIP2A and DPPA4 copy number increase occurred at a relatively high frequency in human HNSCC patient samples. CIP2A but not DPPA4 FISH status was significantly associated with patient survival. CIP2A detection by combining IHC with FISH yielded superior resolution in the prognostication of HNSCC. ConclusionsCIP2A copy number increase is associated with poor patient survival in human HNSCC. We suggest that the reliability and prognostic value of CIP2A detection can be improved by performing FISH analysis to CIP2A IHC positive tumours.en_US
dc.description.sponsorshipFinnish Cancer Associations; Foundation of Finnish Cancer Instituteen_US
dc.description.sponsorshipWe thank Dr. Ilpo Kinnunen for his kind assistance in preparing this manuscript. This work was supported by funding from Finnish Cancer Associations and from Foundation of Finnish Cancer Institute.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.identifier.doi10.1111/jop.12372
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCIP2Aen_US
dc.subjectDPPA4en_US
dc.subjecthead and necken_US
dc.subjectin situ hybridisationen_US
dc.subjectprotein phosphatase 2aen_US
dc.subjectsquamous cell carcinomaen_US
dc.subjectComparative Genomic Hybridizationen_US
dc.subjectPrognostic Indicatoren_US
dc.subjectCancer Cellsen_US
dc.subjectAmplificationen_US
dc.subjectProgressionen_US
dc.subjectStageen_US
dc.subjectGeneen_US
dc.subjectOverexpressionen_US
dc.subjectExpressionen_US
dc.subjectPp2aen_US
dc.titleCopy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinomaen_US
dc.typearticleen_US
dc.relation.ispartofJournal of Oral Pathology & Medicineen_US
dc.departmentRektörlüğe Bağlı Bölümler, Rektörlük, Bilimsel ve Teknolojik Araştırmalar Uygulama ve Araştırma Merkezien_US
dc.authorid0000-0002-3015-0929
dc.authorid0000-0001-7478-3018
dc.authorid0000-0001-5385-7065
dc.authorid0000-0001-6672-6662
dc.authorid0000-0002-5004-0364
dc.authorid0000-0001-7051-7855
dc.identifier.volume45en_US
dc.identifier.issue5en_US
dc.identifier.startpage329en_US
dc.identifier.endpage337en_US
dc.institutionauthorBilgen, Türker
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid56919709700
dc.authorscopusid9242258800
dc.authorscopusid7801581235
dc.authorscopusid7004296768
dc.authorscopusid7006392459
dc.authorscopusid6701723954
dc.authorscopusid6602959003
dc.authorwosidBilgen, Turker/N-6376-2018
dc.authorwosidWestermarck, Jukka/AAL-6464-2020
dc.authorwosidVentela, Sami/I-7253-2018
dc.identifier.wosWOS:000374137600002en_US
dc.identifier.scopus2-s2.0-84946236611en_US
dc.identifier.pmid26436875en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster